Related Experiment Videos
Pharmacology and clinical experience with repaglinide
1Department of Internal Medicine, University of Perugia, via E. dal Pozzo, 06216 Perugia, Italy. mabe@unipg.it
Expert Opinion on Investigational Drugs
|November 4, 2000
Summary
Repaglinide, a prandial glucose regulator, effectively manages Type 2 diabetes by restoring mealtime insulin response. This oral antidiabetic agent offers tighter glycemic control and reduced hypoglycemia risk, with flexible dosing.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Type 2 diabetes is characterized by impaired first-phase insulin response.
- Prandial glucose regulators aim to restore this response for better glycemic control.
- Repaglinide represents a novel class of oral antidiabetic agents.
Purpose of the Study:
- To evaluate repaglinide as a prandial glucose regulator for Type 2 diabetes.
- To assess its efficacy in improving glycemic control and safety profile.
- To compare its effects with other oral antidiabetic agents.
Main Methods:
- Repaglinide administration to patients with Type 2 diabetes.
- Monitoring of insulin profiles and glycemic parameters (HbA1c).
- Assessment of pharmacokinetic properties (absorption, elimination) and safety, including hypoglycemia events.
Main Results:
- Repaglinide rapidly stimulates short-term insulin release, mimicking healthy individuals.
- Significant reduction in HbA1c levels (1.6%) observed, particularly in treatment-naive patients.
- Rapid absorption and elimination reduce hypoglycemia risk and allow dosing flexibility.
- Synergistic effects demonstrated with metformin and potential for combination with NPH-insulin or troglitazone.
Conclusions:
- Repaglinide effectively improves glycemic control in Type 2 diabetes by regulating prandial glucose.
- Its pharmacokinetic profile offers safety advantages, including reduced hypoglycemia risk.
- Repaglinide provides mealtime flexibility and synergistic benefits when combined with other antidiabetic therapies.